Single dose of inactivated Japanese encephalitis vaccine with poly(gamma-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus

Vaccine
Shigefumi OkamotoYasuko Mori

Abstract

Japanese encephalitis (JE) is a serious disease caused by the JE virus (JEV), and vaccination is the only way to prevent the diseases. In Japan, the only JE vaccine currently available is an inactivated vaccine that requires multiple doses for effective protection; therefore, an effective single-dose vaccine is needed. However, no report of an effective protocol for a single dose of JE vaccine in animals has been published. Here, we evaluated the efficacy of a single-dose vaccination in mice to which the JE vaccine was given with or without adjuvant. Biodegradable poly(gamma-glutamic acid) nanoparticles (gamma-PGA-NPs) were used as a test adjuvant. Remarkably, a single dose of JE vaccine with gamma-PGA-NPs enhanced the neutralizing antibody titer, and all of the immunized mice survived a normally lethal JEV infection, while only 50% of the mice that received a single dose of JE vaccine without gamma-PGA-NPs survived. The use of aluminum as the adjuvant showed similar levels of enhanced efficacy. These results show that gamma-PGA-NPs are a novel and safe adjuvant for JE vaccine, and that a single dose of JE vaccine with gamma-PGA-NPs provides effective protection from lethal JEV in mice. A similar protocol, in which a single dos...Continue Reading

References

May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·M HollósiG D Fasman
Sep 5, 2001·The Journal of Infection·T Solomon, M Mallewa
Oct 6, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K LederM E Wilson
Jun 28, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David R Shlim, Tom Solomon
Sep 30, 2004·Nature Immunology·Akiko Iwasaki, Ruslan Medzhitov
Oct 14, 2004·Immunology and Cell Biology·Nikolai Petrovsky, Julio César Aguilar
Feb 26, 2005·Journal of Virology·Yoshio MoriYoshiharu Matsuura
Jun 14, 2005·Nature Medicine·Vladimir P BadovinacJohn T Harty
Aug 30, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Takami AkagiMitsuru Akashi

❮ Previous
Next ❯

Citations

Sep 30, 2009·PLoS Neglected Tropical Diseases·Debapriya Ghosh, Anirban Basu
Mar 8, 2011·Bioresource Technology·Ishwar Bajaj, Rekha Singhal
Feb 15, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Bram SlütterJoke A Bouwstra
Dec 7, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Morin RyuKohji Nishida
Jan 19, 2010·Current Opinion in Microbiology·Allison C Rice-FichtThomas A Ficht
Feb 25, 2010·Journal of Biomaterials Science. Polymer Edition·Takami AkagiMitsuru Akashi
Feb 12, 2009·Journal of Biosciences·Vandana Saxena, Tapan N Dhole
Mar 27, 2020·Current Topics in Medicinal Chemistry·Prasad MinakshiGaya Prasad
Feb 20, 2013·Biologie aujourd'hui·Jose Vicente Gonzalez-AramundizMaría José Alonso
Nov 17, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stephen A KabaDavid E Lanar
Jan 21, 2021·Pathogens·Gabriel Augusto Pires de SouzaLuiz Felipe Leomil Coelho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.